Swedish Orphan Biovitrum SOBI.SE | STOCKHOLM Exch | Medical-Biomed/Biotech | MktCap SEK123.03B Sales SEK23.71B | Shares 356M Float 178M | EPS Due in 98 Days (e)

4686972000 sobi.com Solna, SWEDEN Inc 2001 MGMT owns --

EPS 23 x
EPS Rank 38

Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. It operates through the Haematology, Immunology, and Specialty Care segments. The Haemotology segment focuses on haemophilia medicines Elocta and Alprolix. The immunology segment offers treatment for serious, disabling, and life threatening diseases. The Specialty Care segment specializes in the treatment of genetic and metabolic diseases. The company was founded in 2001 and is headquartered in Solna, Sweden. LESS

ANNUAL - DEC END	2015	2016	2017	2018	2019	2020	2021	2022	2023
EPS SEK	0.23	2.86	4.08	8.57	10.78	10.52	8.67	8.52	7.47
CASH FLOW/SHR SEK	1.81	1.22	4.72	7.38	11.79	16.73	17.60	14.93	13.71
PRETAX MARGIN %	3%	20%	24%	34%	30%	28%	21%	18%	13%
RETURN ON EQUITY %	1%	16%	19%	31%	25%	18%	12%	11%	8%
SALES % CHANGE	24%	61%	25%	40%	56%	7%	2%	21%	18%
SALES (MIL) SEK	3,228	5,204	6,511	9,139	14K	15K	16K	19K	22K

WEEKLY	Sep 6	Sep 13	Sep 20	Sep 27	Oct 4	Oct 11	Oct 18	Oct 25	Oct 29
DATAGRAPH RATING	55	62	60	60	59	59	59	61	62
AVG DAILY VOL (000)	345	351	402	386	389	390	394	401	406
UP DOWN VOLUME	1.8	2.0	1.5	1.6	1.3	1.3	1.5	1.5	1.5
ACCUM/DIST RATING	34	38	19	21	6	3	13	27	25
RELATIVE STRENGTH	78	82	79	80	71	71	70	79	85
GROUP RANK	37	28	21	21	24	22	23	14	15

2024 Estimate		2025 Estimate	
10.26	37%	14.58	42%

Earnings Growth Rate	Sales Growth Rate
2022-24 -8% (13 Stability)	18%
2020-24 -6% (13 Stability)	13%

COMP RATING 89 SMR RATING A
INV T/O 2.2x 45

DEBT %	2021-23	39%	12%	34%
TAX RATE	2021-23	19%	21%	18%
BACKLOG	2021-23	--	--	--

R & D 12.30% BK VAL 3.47x '23
DIV SEK None DIV GR RT--
BETA 0.67(8.00) ALPHA 0.11 (0.06)
2023 EMPLOYEES 1,772 (14%)

Europe Long +10.84% in 10.1 WKS

OH -2%

LOG (Fixed) PRICE

345.60 SEK
-0.800 -0.23%

85
B+

LOG VOLUME
+5%
842.0K

FINANCIALS	Sep 20	Dec 20	Mar 21	Jun 21	Sep 21	Dec 21	Mar 22	Jun 22	Sep 22	Dec 22	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
EPS (SEK)	0.90	4.87	2.26	0.87	1.53	4.02	1.76	0.83	1.46	4.47	3.44	0.71	0.30	3.02	2.35	0.66		2.92e	2.89e	1.94e
EPS % CHANGE	-49%	+10%	-41%	-5%	+70%	-17%	-22%	-5%	-5%	+11%	+95%	-14%	-79%	-32%	-32%	-7%		-3%e	+23%e	+194%e
SALES (MIL SEK)	2,970.0	4,581.0	3,661.0	3,211.0	3,761.0	4,896.0	4,925.0	3,876.0	3,999.0	5,991.0	5,239.0	4,872.0	5,168.0	6,844.0	6,256.0	5,442.0		6,829.3e	6,307.3e	6,159.0e
SALES % CHANGE	+1%	-6%	-21%	+5%	+27%	+7%	+35%	+21%	+6%	+22%	+6%	+26%	+29%	+14%	+19%	+12%		0%e	+1%e	+13%e
EPS % SURPRISE	-10.6%	+15.4%	-9.5%	+39.1%	+4.3%	+23.5%	+27.8%	+15.3%	+10.1%	+6.0%	+5.9%	+39.0%	+46.7%	-15.7%	+0.3%	-13.6%				
FUNDS	388	374	364	340	310	265	295	584	699	781	803	832	829	873	941	920				
SHARES HELD BY FUNDS	88M	68M	66M	58M	48M	38M	47M	61M	66M	66M	67M	66M	75M	88M	95M	94M				

P/E	55
2024 Est.:	33.7
2025 Est.:	23.7
5-yr High:	53
5-yr Low:	11
vs Ind. Avg:	